E-Scape Bio Appoints Anthony Rimac as Chief Financial Officer and Ann Kapoun, Ph.D., as SVP of R&D
SAN FRANCISCO--(BUSINESS WIRE)--Dec 19, 2019--
E-Scape Bio, Inc., a clinical stage, privately held biopharmaceutical company developing novel, precisely-targeted therapeutics for genetically-defined neurodegenerative diseases, today announced the appointment of Tony Rimac as Chief Financial Officer (CFO) and Ann Kapoun, Ph.D., as SVP of R&D.
“Tony and Ann bring a wealth of experience that will serve us well as we continue to advance our research capabilities and prepare for future financings. With over 30 years of experience building and growing biotech organizations through diligent financial planning and execution, Tony will provide financial and strategic leadership that will be instrumental as we advance E-Scape Bio into its next stage of growth,” said Julie Anne Smith, CEO. “Ann is a seasoned leader with a deep understanding of drug development. Her expertise driving programs from discovery through early development will be invaluable as we advance multiple novel, precisely-targeted therapeutics into the clinic.”
Tony brings over 30 years of broad operating and finance experience, including over 20 years of financial leadership within the life sciences industry. Tony joins E-Scape Bio from Chrono Therapeutics Inc., where he served as Chief Financial Officer and Chief Business Officer. Prior to Chrono, he also served as CFO of Aldea Pharmaceuticals, Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS), a neurology focused company where he led the Initial Public Offering, and Aerovance, Inc., a privately held biopharmaceutical company focused on development and commercialization of clinical-stage products for respiratory and allergic diseases. In his 20 years in the life sciences industry, he has worked in biotech, specialty pharmaceuticals, drug delivery, medical devices and digital therapeutics and has raised in excess of $450M in private and public equity, debt capital and partnership financing.
Dr. Kapoun comes to E-Scape with more than two decades of leadership and research experience advancing over 10 drug discoveries through early clinical development. She was most recently SVP of Translational Medicine at OncoMed Pharmaceuticals and previously held scientific leadership roles at ALZA and Scios Inc., a biopharma unit of Johnson & Johnson. Dr. Kapoun received her Ph.D. at Howard Hughes Medical Institute, Indiana University and has coauthored more than 50 scientific publications and patents.
(All bios available at http://www.e-scapebio.com/company/senior-management.php )
About E-Scape Bio
E-Scape Bio is a clinical stage, privately held biopharmaceutical company developing novel, precisely-targeted therapeutics for genetically-defined neurodegenerative diseases. E-Scape’s pipeline includes small molecules targeting known genetic drivers of CNS disorders including ESB1609 for the treatment of CNS lysosomal storage disorders, a Parkinson’s disease program targeting LRRK2 and an Alzheimer’s disease program targeting ApoE4. For additional information, please visit www.e-scapebio.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191219005211/en/
CONTACT: Jason Spark
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: GENERAL HEALTH OTHER HEALTH HEALTH GENETICS PHARMACEUTICAL
SOURCE: E-Scape Bio, Inc.
Copyright Business Wire 2019.
PUB: 12/19/2019 08:00 AM/DISC: 12/19/2019 08:01 AM